506 related articles for article (PubMed ID: 29157685)
21. Optimization techniques for novel c-Met kinase inhibitors.
Sun ZG; Yang YA; Zhang ZG; Zhu HL
Expert Opin Drug Discov; 2019 Jan; 14(1):59-69. PubMed ID: 30518273
[TBL] [Abstract][Full Text] [Related]
22. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.
Gholamin S; Fiuji H; Maftouh M; Mirhafez R; Shandiz FH; Avan A
Curr Drug Targets; 2014; 15(14):1302-11. PubMed ID: 25382190
[TBL] [Abstract][Full Text] [Related]
23. Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors.
Weinberg LR; Albom MS; Angeles TS; Husten J; Lisko JG; McHugh RJ; Milkiewicz KL; Murthy S; Ott GR; Theroff JP; Tripathy R; Underiner TL; Zificsak CA; Dorsey BD
Bioorg Med Chem Lett; 2011 Jan; 21(1):164-7. PubMed ID: 21123062
[TBL] [Abstract][Full Text] [Related]
24. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
Ahn SY; Kim J; Kim MA; Choi J; Kim WH
Anticancer Res; 2017 Mar; 37(3):1127-1138. PubMed ID: 28314274
[TBL] [Abstract][Full Text] [Related]
25. Discovery, optimization and biological evaluation for novel c-Met kinase inhibitors.
Yuan H; Liu Q; Zhang L; Hu S; Chen T; Li H; Chen Y; Xu Y; Lu T
Eur J Med Chem; 2018 Jan; 143():491-502. PubMed ID: 29202410
[TBL] [Abstract][Full Text] [Related]
26. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
27. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
[TBL] [Abstract][Full Text] [Related]
28. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
[TBL] [Abstract][Full Text] [Related]
29. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
30. C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.
Bahrami A; Shahidsales S; Khazaei M; Ghayour-Mobarhan M; Maftouh M; Hassanian SM; Avan A
J Cell Physiol; 2017 Oct; 232(10):2657-2673. PubMed ID: 28075018
[TBL] [Abstract][Full Text] [Related]
31. Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016-Present).
Zhang Q; Zheng P; Zhu W
Molecules; 2020 Jun; 25(11):. PubMed ID: 32521825
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
[TBL] [Abstract][Full Text] [Related]
33. Small molecule c-Met kinase inhibitors: a review of recent patents.
Porter J
Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
[TBL] [Abstract][Full Text] [Related]
34. Targeting the HGF/Met signalling pathway in cancer.
Cecchi F; Rabe DC; Bottaro DP
Eur J Cancer; 2010 May; 46(7):1260-70. PubMed ID: 20303741
[TBL] [Abstract][Full Text] [Related]
35. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
[TBL] [Abstract][Full Text] [Related]
36. Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer.
Zhu S; Liao M; Tan H; Zhu L; Chen Y; He G; Liu B
J Med Chem; 2021 Jul; 64(13):8870-8883. PubMed ID: 34162208
[TBL] [Abstract][Full Text] [Related]
37. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.
Yap TA; Sandhu SK; Alam SM; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2045-58. PubMed ID: 21777195
[TBL] [Abstract][Full Text] [Related]
38. Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening.
Peach ML; Tan N; Choyke SJ; Giubellino A; Athauda G; Burke TR; Nicklaus MC; Bottaro DP
J Med Chem; 2009 Feb; 52(4):943-51. PubMed ID: 19199650
[TBL] [Abstract][Full Text] [Related]
39. Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.
Garon EB; Brodrick P
Drugs; 2021 Apr; 81(5):547-554. PubMed ID: 33638808
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel 1,2,4-triazolo-1,2,4-triazines with thiomethylpyridine hinge binders as potent c-Met kinase inhibitors.
Dadashpour S; Kϋçϋkkılınç TT; Ayazgök B; Hosseinimehr SJ; Chippindale AM; Foroumadi A; Irannejad H
Future Med Chem; 2019 May; 11(10):1119-1136. PubMed ID: 31280674
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]